Synergism between the HSP90 inhibitor AUY922 and the JAK2 inhibitor TG101209 was demonstrated in human CD34+ MPN cells, which exhibited significantly greater apoptosis than did normal hematopoietic progenitor cells. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.